Women | Men | p Value | |
Clinical presentation | |||
Age, mean (SD) | 71.2 years48 | 63.4 years48 | <0.001 |
Prehospital delay from symptom onset | 1.8–7.2 hours16 | 1.4–3.5 hours16 | |
Characteristics of symptoms | More likely to present with atypical symptoms* | More likely to present with chest pain17 | |
CAD in-hospital mortality rate (%) | 60.9–69.149 | 58.6–67.249 | <0.001 |
Pharmacotherapies administered | |||
Aspirin (%) | 87.5–92.748 75 | 90.4–94.748 75 | <0.001 |
Clopidogrel (%) | 43.9–4948 75 | 53.3–5948 75 | <0.001 |
Beta-blockers (%) | 66.8–80.548 75 | 72.6–82.748 75 | <0.001 |
ACE inhibitors/ARBs (%) | 7177 | 7577 | <0.001 |
Lipid-lowering drugs (%) | 55.9–65.848 75 | 69.4–75.348 75 | <0.001 |
Periprocedural bleeding and vascular complications (%) | 4.7–5.419 70 | 1.7–2.719 70 | <0.001 |
PCI rate (%) | 33.348 | 43.848 | <0.001 |
CABG rate (%) | 47.657 | 60.557 | <0.0001 |
References (numbered) can be found in the original article.6
*Including nausea/vomiting (OR 2.29, 95% CI 1.19 to 4.42, p=0.012), dyspnoea (OR 1.82, 95% CI 1.05 to 3.16, p=0.032), palpitations (OR 3.42, 95% CI 1.02 to 11.47, p=0.036) and abnormal pain location (OR 9.61, 95% CI 1.19 to 4.42, p=0.012).
ACS, acute coronary syndrome; ARBs, angiotensin II receptor blockers; CABG, coronary artery bypass grafting; CAD, coronary artery disease; PCI, percutaneous coronary intervention.